PrPC silencing has been shown to sensitize breast cancer cell lines to TRAIL-, Bax, TNF-α, and adjuvant chemotherapy-mediated cell death, which can also be considered as alternative treatments in breast cancer [96] (Figure 3). The gene discussed is TNFSF10; the disease is breast carcinoma.